6/J2%]&*J+B2+L(N*){VP2+#%:)
SYSTEM PROCESSING...
6/J2%]&*J+B2+L(N*){VP2+#%:)
SYSTEM PROCESSING...
Posted: 2025-04-24 04:46:50 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-04-24 04:48:27 UTC
Verified By
Rollup News
The ASPIRE study, published in EHJPharmacotherapy, investigates the efficacy and safety of off-label reduced-dose apixaban in atrial fibrillation patients with a single dose-reduction criterion.
Efficacy and safety of reduced-dose apixaban
Atrial fibrillation treatment
Single dose-reduction criterion
Determining the optimal apixaban dosage for AF patients with specific criteria
Evaluating the safety of off-label reduced-dose apixaban